Cargando…
Lurbinectedin-induced thrombocytopenia: the role of body surface area
Lurbinectedin is an alkylating agent approved for the second-line treatment of small cell lung cancer. Although initial studies showed no association between body surface area (BSA) and drug clearance, the recommended dose is 3.2 mg/m(2) every 3 weeks. This recommendation was based on an exposure–re...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972734/ https://www.ncbi.nlm.nih.gov/pubmed/35362793 http://dx.doi.org/10.1007/s00280-022-04422-6 |